The Next Pandemic! Chikungunya Virus

A major public health announcement issued today at alternative websites across the worldwide web about a natural remedy for Chikungunya virus, a mosquito-borne infectious disease that plagues millions of people living in equatorial countries, is not being issued by major public health agencies.  Instead, a groundbreaking study (see press release below) was privately funded by a small research team of dedicated researchers in Reno, Nevada.

In the aforementioned study, albeit a small pilot human clinical trial, 97% of study subjects experienced a profound and rapid clinical effect, not just a statistical improvement, that would be anticipated to make a demonstrable impact on public health globally.

As such, news of it would normally be issued by The World Health Organization (WHO), its emergency licensure by the Food & Drug Administration, with funding by the National Institutes of Health (NIH).  But news outlets throughout the world are not expected to distribute news of this breakthrough because it doesn’t come with the imprimatur of the WHO or NIH.

Embarrassingly the $5.885 billion National Institutes of Infectious Disease that is solely committed to vaccines while overlooking targeted medicines for control of infectious diseases, was not at the forefront of this breakthrough.

The remedy for Chikungunya virus is but a simple inexpensive amino acid – lysine.  No boost to the stock price of any pharmaceutical company will be announced on Wall Street either.  Sadly, we don’t live in a world where such natural and inexpensive remedies are embraced by public health authorities nor by industry-controlled news media.

A businessman who will remain anonymous whispers to me: “There is no money in lysine therapy.” But there is plenty of money and no cure in vaccines.  A high rate of mutations combined with the lack of long-term immunity is making modern synthetic vaccines against viruses less effective than their predecessors.

This announcement comes on the heels of a news release from GAVI, the Global Vaccine Alliance, that the next pandemic will be Chikungunya virus!  The GAVI press release says Chikungunya could become a “global health threat.”

Well, that could only happen if swarms of mosquitoes choose to proliferate outside of equatorial zones.  The same mosquitoes that are a vector for CHIKG in equatorial countries are prevalent in southern areas of the US (Florida, Texas) but do not carry the virus.

Only 26 Chikungunya cases were reported in the US in 2020.  None of these cases were from mosquito-borne transmission.  All cases involved travelers returning to the US who were exposed overseas.

But some imagined rationale will likely be conjured up to immunize the entire US population for Chikungunya.  Patients with Zika virus were actually flown into the US to pose a contrived health threat that required US research funds to be used to develop a vaccine.  Then public funds are tapped to develop vaccines rather than pharmaceutical R&D funds.  So, pharma companies have incentive to spread infectious disease into the US to tap into the public pools of research funds.

Lysine for COVID-19 coronavirus

Just last month this same research team announced lysine is also a remedy for COVID-19 coronavirus.  The current COVID-19 pandemic was called and the masses coerced to be immunized with experimental vaccines over a virus that kills just one quarter of one-percent of adults residing outside of nursing homes (source: Annals Internal Medicine, Vol. 174, Jan 2021).  Mass vaccination is an overkill.  Targeted drug therapy such as lysine would have averted onerous lockdowns that did not correlate with mortality rates anyway.

These so-called “health institutes” are beholden to commercial interests and embrace a narrow vaccination approach to infectious disease rather than improving natural immunity.

Once the public hears of these natural remedies, given that no proven vaccines exist for Chikungunya virus or COVID-19 coronavirus, and given that these natural remedies pose little or no harm and are inexpensive, they may by word-of-mouth gain wide acceptance without the approval of health overlords.  Such wide public acceptance would reveal the incompetence and outright failure of health agencies to live up to their charters.

Throwing money at infectious diseases has not been productive either.  The Center for Epidemic Preparedness Innovations (CEPI) recently issued $14.1 million to support the development of a vaccine against Chikungunya virusCEPI (Coalition For Epidemic Preparedness) issued an earlier grant for $21 million for the same purpose.

When will this vaccination insanity end?  (See press release below)


              FOR IMMEDIATE RELEASE   May 10, 2021


              Bill Sardi, Knowledge of Health, [email protected]

              Alex Chaihorsky, Bio-Virus Research, Reno, NV
+1(775)742-8811. [email protected]

W O R L D   W I T H O U T    V A C C I N E S



La Verne, CA (May 10, 2021): Using L-lysine, an inexpensive amino acid, an independent, privately-funded team of researchers reports for the first time the rapid resolution of symptoms from a mosquito-borne viral disease (Chikungunya) that plagues human populations in many equatorial countries

Heretofore there have been no licensed vaccine or medicine for this incapacitating viral infection that affects millions of people worldwide.

1000 milligrams of L-lysine, a widely available dietary supplement, was administered to CHIKG-infected individuals with rapid disappearance of symptoms, usually within hours.  Lysine therapy was considered remarkable.

Among 40 acute GHIKG-infected patients:

  • 20 needed only one dose for symptoms to disappear within 3-8 hours;
  • 7 needed a follow-up dose but had near-zero symptoms and only took a second dose when symptoms reappeared;
  • 9 with suspected weak immune systems with established infection required 4-9 days of lysine therapy continually to suppress symptoms.
  • Overall, 39 of 40 subjects experienced resolution of symptoms or fully-controlled symptoms without need for other medications.
  • The 1 failure experienced severe symptoms for 3 days then recovered.

The consumption of coffee was considered a complicating factor and study subjects were advised to cease coffee drinking until symptoms cleared.

Common symptoms of chikungunya (CHIKG) disease, which typically occur 3-12 days after a mosquito bite, are fever and joint pain, with headache, muscle pain, joint swelling or rash also often seen.  Another feature of CHIKG virus is a marked drop in blood platelets that facilitates blood clotting needed for wound healing.  These symptoms may be chronic and/or recurring.

Scientific corroboration

There is corroborative science.  Two-years ago US-based researchers reported that the substitution of lysine for arginine in the CHIKG virus “makes the virus more susceptible to clearance” by white blood cells known as phagocytes (fag-oh-sites) that literally digest pathogens in the blood circulation.

In 2012 screening for molecules that inhibit the growth of CHIKG virus found lysine and vitamin C to be potent inhibitors of the virus.

Diseases without vaccines

Chikungunya virus and COVID-19 coronavirus are two infectious diseases with no licensed vaccine.  Others without a vaccine are malaria, dengue, Zika, Ebola, hepatitis C, varicella-zoster virus, human immunodeficiency virus, and respiratory syncytial virus.

Attempts to curb mosquito populations and to shield humans from mosquito bites appear to be futile given widespread insect proliferation in equatorial zones.  The availability of a simple inexpensive remedy to quell symptoms is more amenable to disease control.  L-lysine is a widely-used dietary component produced in tons for animal feed.

Lysine/arginine balance

A further understanding of dietary factors, more precisely the arginine/lysine balance, needs to be explored.  Theoretically individuals who consume arginine-rich foods like nuts and cocoa/chocolate would experience more acute symptoms.  Consumption of lysine-rich foods such as cheese would re-balance these two amino acids that appear to control susceptibility to the disease.

Lysine for coronavirus too

This same research group earlier reported that L-lysine rapidly resolves symptoms caused by COVID-19 viral infection (ResearchGate).  It has long-been documented that L-lysine is a safe and effective remedy for herpes simplex infections that often emanate as a cold sore on the lips.

While the demand for a larger placebo comparison trial will be anticipated, the overwhelming statistical effectiveness suggests a symptomatic cure is at hand.  No emergency use of an experimental vaccine will be needed for Chikungunya.

The research team at Bio-Virus Research, Inc., Reno, Nevada, founded by Alexander Chaihorsky PhD and Dr. Chris Kagan, with virologist Rony Tal, and human clinical field chief Bo Karlicki in the Dominican Republic, continues to conduct research to address challenging infectious diseases with inexpensive, affordable remedies.  ####

– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –


L-Lysine Treatment of Acute and Chronic Chikungunya Viral Infection (CHIKV)

  • May 2021


For questions and info, please, contact:
Alexander Chaihorsky
Founder and President
Bio-Virus Research Inc.
Reno-NV – Berkeley, CA

[email protected]